Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01577550 · ClinicalTrials.gov registry record · Phase 1
Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
NCT01577550 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 39 participants.
The verdict
NCT01577550, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
Study Summary
Safety, tolerability and efficacy of BI 655066 in male and female patients with moderate to severe psoriasis.
Interventions
- DRUG BI 655066 (very high i.v. dose)
- DRUG Placebo, i.v.
- DRUG BI 655066 (high s.c. dose)
- DRUG BI 655066 (low i.v. dose)
- DRUG BI 655066 (high medium i.v. dose)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2012-04 |
| Est. Completion | 2014-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01577550
The ClinicalTrials.gov registry entry for NCT01577550 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which BI 655066 (very high i.v. dose) is the first listed.
NCT01577550 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01577550 about?
NCT01577550 is a clinical study titled "Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis". Safety, tolerability and efficacy of BI 655066 in male and female patients with moderate to severe psoriasis.
What is the current status of trial NCT01577550?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2012-04. Estimated completion is 2014-05.
What interventions are being tested in trial NCT01577550?
The interventions under investigation include: BI 655066 (very high i.v. dose) (DRUG), Placebo, i.v. (DRUG), BI 655066 (high s.c. dose) (DRUG), BI 655066 (low i.v. dose) (DRUG), BI 655066 (high medium i.v. dose) (DRUG).
Who is sponsoring clinical trial NCT01577550?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.